

Appendix C

Public Notice and Comment Summary

Calcasieu Parish Sec. 110(a)(1) Maintenance Plan

Potpourri

POTPOURRI

Department of Environmental Quality
Office of the Secretary
Legal Affairs Division

Calcasieu Parish Ozone Maintenance Plan

Under the authority of the Louisiana Environmental Quality Act, R. S. 30:2001 et seq., the secretary gives notice that the Office of Environmental Assessment, Plan Development Section, will submit a proposed revision to the ozone maintenance plan for Calcasieu Parish. This revision to the State Implementation Plan (SIP) is mandated under Section 110(a)(1) requirements of the 1990 Clean Air Act Amendments (CAAA).

According to EPA guidance issued May 20, 2005, areas that are designated attainment for the 8-hour ozone National Ambient Air Quality Standards (NAAQS) and are designated attainment for the 1-hour ozone NAAQS with an approved maintenance plan must submit a revision to the SIP.

A public hearing will be held at 1:30 p.m. on April 25, 2007, in the Galvez Building, Oliver Pollock Conference Room, 602 N. Fifth Street, Baton Rouge, LA. Should individuals with a disability need an accommodation in order to participate, please contact Vivian H. Aucoin at (225) 219-3575 or at the address listed below. Interested persons are invited to attend and submit oral comments on the proposal.

All interested persons are invited to submit written comments concerning the SIP revision no later than 4:30 p.m., May 2, 2007, to Vivian H. Aucoin, Office of Environmental Assessment, Box 4314, Baton Rouge, LA 70821-4314 or to FAX (225) 219-3582 or by e-mail to vivian.aucoin@la.gov.

A copy of the SIP revision for Calcasieu Parish may be viewed from 8 a.m. to 4:30 p.m. in the DEQ Public Records Center, Room 127, 602 N. Fifth Street, Baton Rouge, LA. The document is available on the Internet at www.deq.louisiana.gov/portal/Default.aspx?tabid=2381.

Herman Robinson, CPM
Executive Counsel

0703#022

POTPOURRI

Department of Health and Hospitals
Board of Medical Examiners

Public Hearing—Substantive Changes to Proposed Rule;
Collaborative Drug Therapy Management
(LAC 46:XLV.7403 and 7423)

A Notice of Intent concerning the above referenced proposed Rules was published on November 20, 2006 in the *Louisiana Register* (See LR 32:2125-2133), relative to

collaborative drug therapy management between physicians and pharmacists (CDTM). Written comments were invited, received and considered. Certain of those comments suggested substantive changes for sake of consistency with similar proposed Rules noticed by the Louisiana Board of Pharmacy (LBP) (See LR 32:2133-2139). In consideration of such comments the board proposes to amend certain portions of the proposed Rules to more closely parallel those of the LBP by expanding the diseases or conditions subject to CDTM to include dyslipidemia and to rearrange the order of diseases and conditions subject to CDTM to reflect this addition (§7403, Definition of Disease Specific Drug Therapy); and by deleting the prohibition against the use of CDTM for research, clinical or investigational trials, as well as for drugs not identified by the manufacturer for the treatment of a disease or condition subject to CDTM [§7423(F)(6), (10)] and to rearrange the order of items not subject to CDTM to reflect these deletions. Accordingly, the board proposes to amend the proposed Sections as follows.

Title 46

PROFESSIONAL AND OCCUPATIONAL STANDARDS

Part XLV. Medical Profession

Subpart 3. Practice

Chapter 74. Collaborative Drug Therapy Management

Subchapter A. General Provisions

§7403. Definitions

A. ...

Disease Specific Drug Therapy—a specific drug or drugs prescribed by a physician for a specific patient of such physician generally accepted within the standard of care for treatment of one of the following diseases or conditions:

a. - c. ...

d. treatment and prevention of dyslipidemia;

e. smoking cessation therapy;

f. administration of disease specific vaccines to patients 16 years of age and older; and

g. such other drugs, diseases or conditions as may be subsequently recommended by the advisory committee and approved by the board.

AUTHORITY NOTE: Promulgated in accordance with R.S. 37:1270(A)(1), 1270(B)(6) and 37:1164(37).

HISTORICAL NOTE: Promulgated by the Department of Health and Hospitals, Board of Medical Examiners, LR 33:

Subchapter E. Standards of Practice

§7423. Authority, Responsibility and Limitations of Collaborative Drug Therapy Management

A. - E. ...

F. The scope of the collaborative drug therapy management shall not include:

1. - 5. ...

6. initiation or discontinuance of drug therapy by a pharmacist, except as specified in the written protocol;